Therapeutic antibody-drug conjugates targeting CD56-positive cancers
Available for licensing and co-development are antibody-drug conjugates (ADC) that incorporate one of two novel human CD56 antibodies, known as m900 and m906, in combination with a known cytotoxic drug, pyrrolobenzodiazepine (PBD).IC: NCINIH Ref. No.: E-221-2015Advantages: - Fully human antibodies (m900 or m906) targeting CD56 may offer improved properties over the humanized antibody IMGN901 Applications: - Therapeutic for the treatment of neuroblastoma
- Therapeutic for the treatment of other CD56-positive cancers including small cell lung cancer, multiple myeloma, pancreatic cancer, ovarian cancer, acute myeloid leukemia, NK-T lymphoma, and neuroendocrine cancer Development Status: Pre-clinical (in vivo)Updated On: Nov 14, 2017Provider Classifications: Publications: Patent Application: 62/199,707Patent Authority: US ProvisionalLicensing Contacts: Lead Inventor: Inventor IC: NCINCINCIChildren's Hospital of PhiladelphiaInventor Lab URL: https://ccr.cancer.gov/Cancer-and-Inflammation-Program/zhongyu-zhuInv Is lead: LPM Phone: 240-276-5515LPM Email: John.Hewes@nih.govDTDT Classification: TherapeuticsDTDT Description: TherapeuticsPat Filing Date: 2015-07-31Publication Link: http://www.tandfonline.com/action/showCitFormats?doi=10.1080/19420862.2016.1155014Publication Caption: DOI: 10.1080/19420862.2016.1155014Publication Title: Feng, Y, et al. Differen...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: ajoyprabhu3 Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Brain | Cancer | Cancer & Oncology | Hospitals | Leukemia | Lung Cancer | Lymphoma | Myeloma | Neuroblastoma | Neurology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Research